Abstracts tagged "CNS Lupus"

Abstract Number: 024 • 2023 Pediatric Rheumatology Symposium
Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging
Mark DiFrancesco, Ekemini Ogbu, Catherine Robben, Jennifer Huggins and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Prior research suggests that microvascular (MV) changes might be a biomarker for central nervous system (CNS) involvement of patients with systemic lupus erythematosus (SLE).…
Abstract Number: 075 • 2020 Pediatric Rheumatology Symposium
Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus
Taha Moussa¹, Moussa Abdelhak ² and Cuoghi Edens ³, ¹University of Chicago Medicine, Chicago, ²Cambridge GPVTS, Cambridge, United Kingdom, ³University of Chicago, Chicago
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that typically affects multiple organs and can lead to potentially fatal complications. Management of…
Abstract Number: 70 • 2019 ACR/ARP Annual Meeting
Angiotensin Receptor Blockers Prevent Loss of Dendritic Complexity in a Lupus Mouse Model of Cognitive Impairment
Lara El Khoury¹, Nina Kello ¹, Kristiana Hanna ², Bruce Volpe ³ and Betty Diamond ⁴, ¹Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, ²Albany Medical College, Albany, NY, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Cognitive dysfunction affects the majority of patients with systemic lupus erythematosus (SLE), however it is grossly under-recognized, the pathogenesis is poorly understood, and no…
Abstract Number: 754 • 2018 ACR/ARHP Annual Meeting
Determinants of Major Neurocognitive Disorder (Vascular Dementia) in SLE: The Importance of Treatment Adherence of SLE Disease Activity and Cardiovascular Risk Factors
Jamal A. Mikdashi, Div of Rheumatology, Univ of Maryland Schl of Med, Baltimore, MD; Medicine/Rheum & Clinc Immun, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Factors associated with neuropsychiatric damage in SLE has been described. Yet, determinants of progression of small vessel related brain injury, and major neurocognitive disorder-vascular…
Abstract Number: 935 • 2018 ACR/ARHP Annual Meeting
Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Lipocalin-2
Elise Mike¹, Hadijat M. Makinde², Maria Gulinello³, Kamala Vanarsa⁴, Leal Herlitz⁵, Chandra Mohan⁶, Chi Chiu Mok⁷, John G. Hanly⁸, Deborah R. Winter⁹, Carla M. Cuda¹⁰ and Chaim Putterman¹¹, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, ⁴Biomedical Engineering, University of Houston, houston, TX, ⁵Cleveland Clinic, Cleveland, OH, ⁶Department of Biomedical Engineering, University of Houston, Houston, Texas, USA, Houston, TX, ⁷Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ⁸Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁹Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Although the pathogenesis of neuropsychiatric lupus (NPSLE) is not fully understood, neuroinflammation plays a major role in disease. Lipocalin-2, an acute phase reactant protein…
Abstract Number: 2095 • 2018 ACR/ARHP Annual Meeting
Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
Michelle Huang¹, Ariel Stock² and Chaim Putterman³, ¹Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Despite the many lupus patients affected by neuropsychiatric signs and symptoms, the pathogenesis of neuropsychiatric disease in SLE remains unclear. MRL-lpr/lpr mice, a classic…
Abstract Number: 113 • 2017 Pediatric Rheumatology Symposium
Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis
Eyal Muscal¹, Heather Van Mater², Tania Cellucci³, Dominic Co⁴, Jennifer Frankovich⁵, Marisa S. Klein-Gitelman⁶, Marinka Twilt⁷ and Susanne Benseler⁸, ¹Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Pediatrics/ Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³McMaster University, hamilton, ON, Canada, ⁴Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁵Pediatrics, Standford University, Palo Alto, CA, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Paediatrics, University Of Calgary, Calgary, AB, Canada, ⁸Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Autoimmune encephalitis (AE) encompasses a spectrum of immune-mediated brain disorders that cause severe neuropsychiatric manifestations. These disorders often lead to protracted hospital stays, complex…
Abstract Number: 1812 • 2016 ACR/ARHP Annual Meeting
Impact of Severe Organic CNS Involvement in Cognitive Function in a Cohort of Systemic Lupus Erythematosus Patients
Christina V. Golemati¹, Eleni Kampylafka¹, Charalampos Papageorgiou², Panayiotis G Vlachoyiannopoulos¹ and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²1st Psychiatry, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Our purpose was to investigate cognitive dysfunction (CD) in a cohort of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) patients (n=16) with severe central nervous system…
Abstract Number: 2056 • 2016 ACR/ARHP Annual Meeting
Choroid Plexus Infiltrates in Lupus Model (MRL/lpr) Mice Represent Tertiary Lymphoid Structures, Shedding Light on the Immunological Mechanisms of Neuropsychiatric Lupus
Ariel Stock¹, Sivan Gelb², Ayal Ben-Zvi² and Chaim Putterman³, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Hebrew University, Jerusalem, Israel, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: MRL/lpr mice develop an overt neuropsychiatric phenotype including depression and cognitive dysfunction, similar to diffuse neuropsychiatric manifestations of human lupus. Additionally, MRL/lpr mice display…
Abstract Number: 904 • 2015 ACR/ARHP Annual Meeting
Intracerebroventricular Tweak (TNF-like weak inducer of apoptosis) Induces Depressive-like Behavior and Cognitive Dysfunction in Non-Autoimmune Mice
Jing Wen¹, Christopher Chen¹, Ariel Stock¹, Jessica Doerner¹, Maria Gulinello¹ and Chaim Putterman^1,2, ¹Albert Einstein College of Medicine, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric lupus (NPSLE) is a common disease manifestation in lupus patients; however, the underlying mechanisms are not fully understood. TWEAK is a cytokine member…
Abstract Number: 2902 • 2015 ACR/ARHP Annual Meeting
The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study
John G. Hanly¹, Qiuju Li², Li Su³, Murray Urowitz^4,5, Juanita Romero-Diaz⁶, C. Gordon⁷, Sang-Cheol Bae⁸, Sasha R Bernatsky⁹, Ann Clarke¹⁰, Daniel J Wallace¹¹, Joan T. Merrill¹², David A. Isenberg¹³, Anisur Rahman¹⁴, Ellen M. Ginzler¹⁵, Michelle Petri¹⁶, Ian N. Bruce¹⁷, Mary Anne Dooley¹⁸, Paul Fortin¹⁹, Dafna D. Gladman²⁰, Jorge Sanchez-Guerrero²¹, Kristján Steinsson²², Rosalind Ramsey-Goldman²³, Munther Khamashta²⁴, Cynthia Aranow²⁵, Graciela S. Alarcon²⁶, Barri J. Fessler²⁷, Susan Manzi²⁸, Ola Nived²⁹, Gunnar K. Sturfelt³⁰, Asad Zoma³¹, Ronald F. van Vollenhoven³², Manuel Ramos-Casals³³, Guillermo Ruiz-Irastorza³⁴, S. Sam Lim³⁵, Kenneth C. Kalunian³⁶, Murat Inanc³⁷, Diane L. Kamen³⁸, Christine A. Peschken³⁹, Søren Jacobsen⁴⁰, Anca Askanase⁴¹, Chris Theriault⁴² and Vernon Farewell⁴³, ¹Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ²MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ³Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴Rheumatology, TWH, Toronto, ON, Canada, ⁵Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁷School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Division of Rheumatolog, McGill Unversity Health Cener, Montreal, QC, Canada, ¹⁰Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁴Centre for Rheumatology Research, U College of London, London, United Kingdom, ¹⁵Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁶Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ¹⁷Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁸UNC Kidney Centre, Chapel Hill, NC, ¹⁹Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, ²⁰Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²²Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²⁵Feinstein Institute for Medical Research, Manhasset, NY, ²⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁷UAB, Birmingham, AL, ²⁸Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁹Rheumatology, Inst of Clinical sciences, Lund, Sweden, ³⁰Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³¹Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³³Autoimmune Diseases, IDIBAPS, Hospital Clinic, Barcelona, Spain, ³⁴Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³⁵Emory University School of Medicine, Atlanta, GA, ³⁶Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁷Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁸Medicine, Medical University of South Carolina, Charleston, SC, ³⁹Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴⁰Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴¹Columbia University College of Physicians & Surgeons, New York, NY, ⁴²Dept of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴³Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) disease in patients with SLE includes cerebrovascular events. We determined the frequency, characteristics and attribution in a large, multi-ethnic/racial, inception cohort of…
Abstract Number: 2645 • 2014 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Pulse Cyclophosphamide for Neuropsychiatric Systemic Lupus Erythematosus: A Two-Centre Experience
Antonis Fanouriakis¹, Cristina Pamfil², Laura O. Damian³, Ioana Felea³, Emmanuel Mihali⁴, Ileana Filipescu², Theofanis Karageorgas⁵, Prodromos Sidiropoulos⁶, Simona Rednic², George Bertsias^6,7 and Dimitrios Boumpas^5,7,8, ¹Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ²Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, ³Rheumatology, Emergency Clinical County Hospital Cluj, Cluj-Napoca, Romania, ⁴Emergency Clinical County Hospital Cluj, Cluj-Napoca, Romania, ⁵Clinical Immunology and Rheumatology, "Attikon" University Hospital of Athens, Athens, Greece, ⁶Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁷Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece, ⁸Biomedical Research Foundation, Academy of Athens, Athens, Greece
Background/Purpose Cyclophosphamide (CYC) is often used in severe neuropsychiatric systemic lupus erythematosus. However, data on its use rely on small case series and a single…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].